Anzeige
Mehr »
Freitag, 05.12.2025 - Börsentäglich über 12.000 News
Das Timing könnte nicht besser sein - Durchbruchsjahr 2026 für Myriad
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
21:06$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today3
20:01Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?2
19:42Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?8
16:42Trium Capital discloses 1.16% stake in Avadel Pharmaceuticals1
16:34Trium Kapital meldet Beteiligung von 1,16 % an Avadel Pharmaceuticals2
16:30Erste Group upgrades Amgen stock rating to Buy from Hold on obesity drug10
16:30EILMELDUNG: Biontech-Aktie auffällig ruhig - steht der Ausbruch kurz bevor?
16:22Citadel legt 1,2 %-Anteil an Avadel Pharmaceuticals offen1
16:22Erste Group stuft Amgen-Aktie wegen Adipositas-Medikament auf 'Kaufen' hoch12
16:18Citadel Group discloses 1.2% stake in Avadel Pharmaceuticals1
16:10Merck's Keytruda SC launch in Germany faces new hurdle as Halozyme scores preliminary injunction6
16:10ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study1
16:06Insider Transaction: August J Troendle Sells $394K Worth Of Medpace Holdings Shares1
16:02Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?12
15:58Janus Henderson meldet 3,84 %-Beteiligung an Avadel Pharmaceuticals1
15:42Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome212WESTON (dpa-AFX) - Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studies evaluating zorevunersen...
► Artikel lesen
15:30Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting3
15:30Amylyx's ALS drug AMX0114 shows positive early safety data1
15:10Biogen Inc.: Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting227-Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in...
► Artikel lesen
15:10Denali Enters Into a $275M Funding Deal With Royalty Pharma1
Weiter >>